KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
KD025
Sponsor
Kadmon, a Sanofi Company